{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T05:13:10Z","timestamp":1739077990136,"version":"3.37.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The SARS-CoV-2 pandemic was a challenge for health care systems worldwide. People with pre-existing chronic diseases have been identified as vulnerable patient groups. Furthermore, some of the drugs used for these chronic diseases such as antihypertensive drugs have been discussed as possible influencing factors on the progression of COVID-19. This study examines the effect of medication- and morbidity-associated risk factors suspected to moderate the disease course and progression of COVID-19.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study is based on claims data of the Techniker Krankenkasse, Germany\u2019s largest statutory health insurance. The data cover the years 2020 to 2022 and include insured persons with COVID-19 diagnosis from both the outpatient and inpatient sectors and a control of insured persons without COVID-19 diagnosis. We conducted a matched case-control study and matched each patient with an inpatient diagnosis of COVID-19 to (a) 10 control patients and (b) one patient with an outpatient diagnosis of COVID-19 to form two study cohorts. We performed a descriptive analysis to describe the proportion of patients in the two cohorts who were diagnosed with comorbidities or medication use known to influence the risk of COVID-19 progression. Multiple logistic regression models were used to identify risk factors for disease progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the first study period the first study cohort comprised a total of 150,018 patients (13,638 cases hospitalised with COVID-19 and 136,380 control patients without a COVID-19 infection). Study cohort 2 included 27,238 patients (13,619 patients hospitalised with COVID-19 and 13,619 control patients with an outpatient COVID-19 diagnosis). Immunodeficiencies and use of immunosuppressives were strongest risk modifying factors for hospitalization in both study populations. Other comorbidities associated with hospitalization were diabetes, hypertension, and depression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We have shown that hospitalisation with COVID-19 is associated with past medical history and medication use. Furthermore, we have demonstrated the ability of claims data as a timely available data source to identify risk factors for COVID-19 severity based on large numbers of patients. Given our results, claims data have the potential to be useful as part of a surveillance protocol allowing early-stage access to epidemiological data in future pandemics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12889-024-21110-7","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T09:17:49Z","timestamp":1739006269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 in the years 2020 to 2022 in Germany: effects of comorbidities and co-medications based on a large-scale database analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Roland","family":"Linder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Peltner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoli","family":"Astvatsatourov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willy","family":"Gomm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Haenisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"21110_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-021-04188-6","volume":"600","author":"J Li","year":"2021","unstructured":"Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-CoV-2. Nature. 2021;600:408\u201318. https:\/\/doi.org\/10.1038\/s41586-021-04188-6","journal-title":"Nature"},{"key":"21110_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1126\/science.abc8169","volume":"370","author":"M Worobey","year":"2020","unstructured":"Worobey M, Pekar J, Larsen BB, Nelson MI, Hill V, Joy JB, et al. The emergence of SARS-CoV-2 in Europe and North America. Science. 2020;370:564\u201370. https:\/\/doi.org\/10.1126\/science.abc8169","journal-title":"Science"},{"key":"21110_CR3","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.3390\/cancers13194749","volume":"13","author":"M-A Benderra","year":"2021","unstructured":"Benderra M-A, Aparicio A, Leblanc J, Wassermann D, Kempf E, Galula G, et al. Clinical characteristics, Care trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer patients: a Multicenter Cohort Study. Cancers. 2021;13:4749. https:\/\/doi.org\/10.3390\/cancers13194749","journal-title":"Cancers"},{"key":"21110_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41479-021-00092-9","volume":"13","author":"A Aslan","year":"2021","unstructured":"Aslan A, Aslan C, Zolbanin NM, Jafari R. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia. 2021;13:14. https:\/\/doi.org\/10.1186\/s41479-021-00092-9","journal-title":"Pneumonia"},{"key":"21110_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12985-022-01814-1","volume":"19","author":"S Montazersaheb","year":"2022","unstructured":"Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, Tarhriz V, Farjami A, Ghasemian Sorbeni F, et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. 2022;19:92. https:\/\/doi.org\/10.1186\/s12985-022-01814-1","journal-title":"Virol J"},{"key":"21110_CR6","doi-asserted-by":"publisher","first-page":"e0247461","DOI":"10.1371\/journal.pone.0247461","volume":"16","author":"A Booth","year":"2021","unstructured":"Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS ONE. 2021;16:e0247461. https:\/\/doi.org\/10.1371\/journal.pone.0247461","journal-title":"PLoS ONE"},{"key":"21110_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10654-021-00722-y","volume":"36","author":"J Elliott","year":"2021","unstructured":"Elliott J, Bodinier B, Whitaker M, Delpierre C, Vermeulen R, Tzoulaki I, et al. COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors. Eur J Epidemiol. 2021;36:299\u2013309. https:\/\/doi.org\/10.1007\/s10654-021-00722-y","journal-title":"Eur J Epidemiol"},{"key":"21110_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/all.14657","volume":"76","author":"Y Gao","year":"2021","unstructured":"Gao Y, Ding M, Dong X, Zhang J, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76:428\u201355. https:\/\/doi.org\/10.1111\/all.14657","journal-title":"Allergy"},{"key":"21110_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430\u20136. https:\/\/doi.org\/10.1038\/s41586-020-2521-4","journal-title":"Nature"},{"key":"21110_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","volume":"94","author":"J Yang","year":"2020","unstructured":"Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91\u20135. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.017","journal-title":"Int J Infect Dis"},{"key":"21110_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15010-020-01509-1","volume":"49","author":"D Wolff","year":"2021","unstructured":"Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. 2021;49:15\u201328. https:\/\/doi.org\/10.1007\/s15010-020-01509-1","journal-title":"Infection"},{"key":"21110_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/v14020275","volume":"14","author":"L Hobohm","year":"2022","unstructured":"Hobohm L, Sagoschen I, Barco S, Schmidtmann I, Espinola-Klein C, Konstantinides S, et al. Trends and Risk factors of In-Hospital mortality of patients with COVID-19 in Germany: results of a large Nationwide Inpatient Sample. Viruses. 2022;14:275. https:\/\/doi.org\/10.3390\/v14020275","journal-title":"Viruses"},{"key":"21110_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/23744235.2021.1982141","volume":"54","author":"R Jucknewitz","year":"2022","unstructured":"Jucknewitz R, Weidinger O, Schramm A. Covid-19 risk factors: statistical learning from German healthcare claims data. Infect Dis. 2022;54:110\u20139. https:\/\/doi.org\/10.1080\/23744235.2021.1982141","journal-title":"Infect Dis"},{"key":"21110_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S2213-2600(20)30316-7","volume":"8","author":"C Karagiannidis","year":"2020","unstructured":"Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respiratory Med. 2020;8:853\u201362. https:\/\/doi.org\/10.1016\/S2213-2600(20)30316-7","journal-title":"Lancet Respiratory Med"},{"key":"21110_CR15","doi-asserted-by":"publisher","first-page":"e1003374","DOI":"10.1371\/journal.pmed.1003374","volume":"17","author":"PM McKeigue","year":"2020","unstructured":"McKeigue PM, Weir A, Bishop J, McGurnaghan SJ, Kennedy S, McAllister D, et al. Rapid Epidemiological Analysis of Comorbidities and treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control study. PLoS Med. 2020;17:e1003374. https:\/\/doi.org\/10.1371\/journal.pmed.1003374","journal-title":"PLoS Med"},{"key":"21110_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/23744235.2023.2267134","volume":"56","author":"C Leding","year":"2024","unstructured":"Leding C, Clausen CL, Roldgaard MS, Benfield T. Temporal trends in 90-day survival of hospitalised individuals during two years of the COVID-19 pandemic in Denmark. Infect Dis. 2024;56:42\u201351. https:\/\/doi.org\/10.1080\/23744235.2023.2267134","journal-title":"Infect Dis"},{"key":"21110_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2022.04.048","volume":"121","author":"Y Xia","year":"2022","unstructured":"Xia Y, Ma H, Buckeridge DL, Brisson M, Sander B, Chan A, et al. Mortality trends and length of stays among hospitalized patients with COVID-19 in Ontario and Qu\u00e9bec (Canada): a population-based cohort study of the first three epidemic waves. Int J Infect Dis. 2022;121:1\u201310. https:\/\/doi.org\/10.1016\/j.ijid.2022.04.048","journal-title":"Int J Infect Dis"},{"key":"21110_CR18","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respiratory Med. 2020;8:e21. https:\/\/doi.org\/10.1016\/S2213-2600(20)30116-8","journal-title":"Lancet Respiratory Med"},{"key":"21110_CR19","doi-asserted-by":"publisher","unstructured":"Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Mayo Clinic Proceedings. 2020;95:1222\u201330. https:\/\/doi.org\/10.1016\/j.mayocp.2020.03.026","DOI":"10.1016\/j.mayocp.2020.03.026"},{"key":"21110_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(20)30628-0","journal-title":"Lancet"},{"key":"21110_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0140-6736(20)30691-7","volume":"395","author":"AI Ritchie","year":"2020","unstructured":"Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet. 2020;395:1111. https:\/\/doi.org\/10.1016\/S0140-6736(20)30691-7","journal-title":"Lancet"},{"key":"21110_CR22","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"21110_CR23","unstructured":"Federal Ministry of Health. Long-Term Care Guide 2020."},{"key":"21110_CR24","doi-asserted-by":"publisher","first-page":"993662","DOI":"10.3389\/fpubh.2022.993662","volume":"10","author":"J Gerken","year":"2022","unstructured":"Gerken J, Zapata D, Kuivinen D, Zapata I. Comorbidities, sociodemographic factors, and determinants of health on COVID-19 fatalities in the United States. Front Public Health. 2022;10:993662. https:\/\/doi.org\/10.3389\/fpubh.2022.993662","journal-title":"Front Public Health"},{"key":"21110_CR25","doi-asserted-by":"publisher","first-page":"e0258154","DOI":"10.1371\/journal.pone.0258154","volume":"16","author":"E Ge","year":"2021","unstructured":"Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: a population-based cohort study. PLoS ONE. 2021;16:e0258154. https:\/\/doi.org\/10.1371\/journal.pone.0258154","journal-title":"PLoS ONE"},{"key":"21110_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10654-021-00732-w","volume":"36","author":"J Bergman","year":"2021","unstructured":"Bergman J, Ballin M, Nordstr\u00f6m A, Nordstr\u00f6m P. Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. Eur J Epidemiol. 2021;36:287\u201398. https:\/\/doi.org\/10.1007\/s10654-021-00732-w","journal-title":"Eur J Epidemiol"},{"key":"21110_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","volume":"180","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors Associated with Mortality among patients with COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020;180:1345. https:\/\/doi.org\/10.1001\/jamainternmed.2020.3539","journal-title":"JAMA Intern Med"},{"key":"21110_CR28","doi-asserted-by":"publisher","first-page":"e1003321","DOI":"10.1371\/journal.pmed.1003321","volume":"17","author":"SL Harrison","year":"2020","unstructured":"Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis. PLoS Med. 2020;17:e1003321. https:\/\/doi.org\/10.1371\/journal.pmed.1003321","journal-title":"PLoS Med"},{"key":"21110_CR29","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1017\/S2045796023000719","volume":"32","author":"P Molero","year":"2023","unstructured":"Molero P, Reina G, Blom JD, Mart\u00ednez-Gonz\u00e1lez M\u00c1, Reinken A, De Kloet ER, et al. COVID-19 risk, course and outcome in people with mental disorders: a systematic review and meta-analyses. Epidemiol Psychiatr Sci. 2023;32:e61. https:\/\/doi.org\/10.1017\/S2045796023000719","journal-title":"Epidemiol Psychiatr Sci"},{"key":"21110_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12916-021-01907-8","volume":"19","author":"PM McKeigue","year":"2021","unstructured":"on behalf of Public Health Scotland COVID-19 Health Protection Study Group, McKeigue PM, Kennedy S, Weir A, Bishop J, McGurnaghan SJ, et al. Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. BMC Med. 2021;19:51. https:\/\/doi.org\/10.1186\/s12916-021-01907-8","journal-title":"BMC Med"},{"key":"21110_CR31","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","volume":"26","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, S\u00e1nchez-Rico M, Vernet R, Beeker N, Jannot A-S, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26:5199\u2013212. https:\/\/doi.org\/10.1038\/s41380-021-01021-4","journal-title":"Mol Psychiatry"},{"key":"21110_CR32","doi-asserted-by":"publisher","first-page":"e2133090","DOI":"10.1001\/jamanetworkopen.2021.33090","volume":"4","author":"T Oskotsky","year":"2021","unstructured":"Oskotsky T, Mari\u0107 I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4:e2133090. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.33090","journal-title":"JAMA Netw Open"},{"key":"21110_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.euroneuro.2023.03.011","volume":"71","author":"I Visos-Varela","year":"2023","unstructured":"Visos-Varela I, Zapata-Cachafeiro M, Pi\u00f1eiro-Lamas M, Carracedo-Mart\u00ednez E, Saez M, Herdeiro MT, et al. Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: a population-based study. Eur Neuropsychopharmacol. 2023;71:96\u2013108. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.03.011","journal-title":"Eur Neuropsychopharmacol"},{"key":"21110_CR34","doi-asserted-by":"publisher","first-page":"13462","DOI":"10.1038\/s41598-024-64260-9","volume":"14","author":"MI Prasanth","year":"2024","unstructured":"Prasanth MI, Wannigama DL, Reiersen AM, Thitilertdecha P, Prasansuklab A, Tencomnao T, et al. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications. Sci Rep. 2024;14:13462. https:\/\/doi.org\/10.1038\/s41598-024-64260-9","journal-title":"Sci Rep"},{"key":"21110_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s40001-022-00824-7","volume":"27","author":"S SeyedAlinaghi","year":"2022","unstructured":"SeyedAlinaghi S, Karimi A, Barzegary A, Mojdeganlou H, Vahedi F, Mirghaderi SP, et al. COVID-19 mortality in patients with immunodeficiency and its predictors: a systematic review. Eur J Med Res. 2022;27:195. https:\/\/doi.org\/10.1186\/s40001-022-00824-7","journal-title":"Eur J Med Res"},{"key":"21110_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/imj.15142","volume":"51","author":"D Tassone","year":"2021","unstructured":"Tassone D, Thompson A, Connell W, Lee T, Ungaro R, An P, et al. Immunosuppression as a risk factor for COVID -19: a meta\u2010analysis. Intern Med J. 2021;51:199\u2013205. https:\/\/doi.org\/10.1111\/imj.15142","journal-title":"Intern Med J"},{"key":"21110_CR37","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1007\/s11606-021-07152-2","volume":"36","author":"FS Velayos","year":"2021","unstructured":"Velayos FS, Dusendang JR, Schmittdiel JA. Prior immunosuppressive therapy and severe illness among patients diagnosed with SARS-CoV-2: a community-based study. J GEN INTERN MED. 2021;36:3794\u2013801. https:\/\/doi.org\/10.1007\/s11606-021-07152-2","journal-title":"J GEN INTERN MED"},{"key":"21110_CR38","doi-asserted-by":"publisher","first-page":"2100769","DOI":"10.1183\/13993003.00769-2021","volume":"59","author":"D Ward","year":"2022","unstructured":"Ward D, G\u00f8rtz S, Thomson Ernst M, Andersen NN, Kj\u00e6r SK, Hallas J, et al. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. Eur Respir J. 2022;59:2100769. https:\/\/doi.org\/10.1183\/13993003.00769-2021","journal-title":"Eur Respir J"},{"key":"21110_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/hpm.868","volume":"22","author":"G Kastberg","year":"2007","unstructured":"Kastberg G, Siverbo S. Activity-based financing of health care\u2013\u2013experiences from Sweden. Health Plann Manage. 2007;22:25\u201344. https:\/\/doi.org\/10.1002\/hpm.868","journal-title":"Health Plann Manage"},{"key":"21110_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/thoraxjnl-2021-217080","volume":"77","author":"AK Clift","year":"2022","unstructured":"Clift AK, Von Ende A, Tan PS, Sallis HM, Lindson N, Coupland CAC, et al. Smoking and COVID-19 outcomes: an observational and mendelian randomisation study using the UK Biobank cohort. Thorax. 2022;77:65\u201373. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-217080","journal-title":"Thorax"},{"key":"21110_CR41","doi-asserted-by":"publisher","first-page":"e13128","DOI":"10.1111\/obr.13128","volume":"21","author":"BM Popkin","year":"2020","unstructured":"Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21:e13128. https:\/\/doi.org\/10.1111\/obr.13128","journal-title":"Obes Rev"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-21110-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-21110-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-21110-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T09:17:56Z","timestamp":1739006276000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-21110-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21110"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-21110-7","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"525"}}